Emerging therapies for breast cancer

Emerging therapies for breast cancer

Abstract HER2 and CDK4/6 are undoubted two most important biological targets for breast cancer. Anti-HER2 treatments enhance objective response and progression-free survival/disease-free survival as well as overall survival. Three CDK4/6 inhibitors consistently improve objective response and progres...

Full description

Bibliographic Details
Main Authors: Xichun Hu, Wei Huang, Minhao Fan
Format: Article
Language:English
Published: BioMed Central 2017-04-01
Series:Journal of Hematology & Oncology
Subjects:
Breast cancer
CDK4/6 inhibitors
SERD
PD1 and PD-L1 antibodies
PARP inhibitors
Fulvestrant
Online Access:http://link.springer.com/article/10.1186/s13045-017-0466-3

Internet

http://link.springer.com/article/10.1186/s13045-017-0466-3

Similar Items